Encision Reports Third Quarter Fiscal Year 2020 Results

BOULDER, Colo., Feb. 6, 2020 /PRNewswire/ -- Encision Inc. ECIA, a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2020 third quarter that ended December 31, 2019.

The Company posted quarterly net revenue of $2.04 million for a quarterly net income of $70 thousand, or $0.01 per diluted share. These results compare to net revenue of $2.12 million for a quarterly net loss of $84 thousand, or $(0.01) per diluted share, in the year-ago quarter. Gross margin on net revenue was 53% in the fiscal 2019 and 50% in the fiscal 2018 third quarters. Gross margin on net revenue was higher in this year's third quarter than last year's third quarter principally as a result of lower labor costs, per unit of inventory.

The Company posted nine months net revenue of $5.89 million for a nine months net loss of $82 thousand, or $(0.01) per diluted share. These results compare to net revenue of $6.72 million for a nine months net loss of $53 thousand, or $0.00 per diluted share, in the year-ago nine months. Gross margin on net revenue was 52% in the fiscal 2019 nine months and 53% in the fiscal 2018 nine months. Gross margin on net revenue was lower in the fiscal 2019 nine months as compared to the fiscal 2018 nine months primarily as a result of higher material costs, especially as a result of tariffs on our material costs and higher labor and overhead costs, per unit of inventory.

"We look forward to the fourth fiscal quarter and next fiscal year," said Greg Trudel, President and CEO of Encision Inc. "We are presently in discussions with a major healthcare company regarding collaboration on an engineering project that would incorporate our AEM® Technology as well as offer the potential for a long-term partnership. We are also looking forward to a new product introduction in the next fiscal year that will open new account opportunities, enable customers to reduce per procedure costs, and drive revenue growth for Encision."

Encision Inc. designs and markets a portfolio of high performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2019 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:            Mala Ray, Encision Inc., 303-444-2600, mray@encision.com

Encision Inc.

Unaudited Condensed Statements of Operations

(in thousands, except per share information)







Three Months Ended

Nine Months Ended





December 31,

2019



December 31,

2018



December 31,

2019



December 31,

2018

Net revenue



$2,039



$2,117



$5,892



$6,718

Cost of revenue



956



1,055



2,827



3,149

Gross profit



1,083



1,062



3,065



3,569

Operating expenses:

















    Sales and marketing



544



645



1,612



2,077

    General and administrative



294



312



943



954

    Research and development



159



189



568



543

        Total operating expenses



997



1,146



3,123



3,574

Operating income (loss)



86



(84)



(58)



(5)

Interest expense and other expense, net



(16)



––



(24)



(48)

Income (loss) before provision for income

    taxes



70



(84)



(82)



(53)

Provision for income taxes



––



––



––



––

Net income (loss)



$    70



$ (84)



$(82)



$ (53)

Net income (loss) per share—basic and

    diluted



$ 0.01



$(0.01)



$(0.01)



$0.00

Weighted average number of shares—

    basic



 

11,578



 

10,799



 

11,565



 

10,722

Weighted average number of shares—

    diluted



 

11,631



 

10,799



 

11,565



 

10,722

 

Encision Inc.

Unaudited Condensed Balance Sheets

(in thousands)







December 31,

2019



  March 31,

2019

ASSETS









Cash and cash equivalents



$     195



$    273

Restricted cash



––



25

Accounts receivable, net



1,059



1,009

Inventories, net



1,360



1,473

Prepaid expenses



119



130

    Total current assets



2,733



2,910

Equipment, net



211



250

Patents, net



234



249

Right of use asset



1,383



––

Other assets



19



19

    Total assets



$ 4,580



$ 3,428

LIABILITIES AND SHAREHOLDERS' EQUITY









Accounts payable



$   510



$   579

Accrued compensation



190



296

Other accrued liabilities



101



126

Accrued lease liability



271



––

    Total current liabilities



1,072



1,001

Accrued lease liability



1,216



––

Deferred rent



––



75

    Total liabilities



2,288



1,076

Common stock and additional paid-in capital



24,224



24,202

Accumulated (deficit)



(21,932)



(21,850)

    Total shareholders' equity



2,292



2,352

    Total liabilities and shareholders' equity



$ 4,580



$ 3,428

 

Encision Inc.

Unaudited Condensed Statements of Cash Flows

(in thousands)







Nine Months Ended





December 31,

2019



   December 31,

2018

Operating activities:









    Net (loss)



$ (82)



$ (53)

    Adjustments to reconcile net income (loss) to cash

        generated by (used in) operating activities:









    Depreciation and amortization



112



141

    Share-based compensation expense



22



37

    (Recovery from) provision for doubtful accounts, net



10



(1)

    (Recovery from) provision for inventory obsolescence, net



(9)



24

    Changes in operating assets and liabilities:









        Right of use asset, net



30



––

        Accounts receivable     



(59)



(61)

        Inventories



121



22

        Prepaid expenses and other assets



11



(55)

        Accounts payable



(69)



224

        Accrued compensation and other accrued liabilities



(132)



(150)

            Net cash generated by (used in) operating activities



(45)



128











Investing activities:









    Acquisition of property and equipment



(53)



(10)

    Patent costs



(5)



(5)

            Net cash (used in) investing activities



(58)



(15)











Financing activities:









    Proceeds from the issuance of common stock



––



350

            Net cash generated by financing activities



––



350











Net increase (decrease) in cash, cash equivalents and

   restricted cash



(103)



463

Cash, cash equivalents and restricted cash, beginning of

       period



298



139

Cash, cash equivalents and restricted cash, end of period



$    195



$ 602













 

Cision View original content:http://www.prnewswire.com/news-releases/encision-reports-third-quarter-fiscal-year-2020-results-300999730.html

SOURCE Encision Inc.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsSmall CapPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!